Serum Anti-HIV 1 & 2 Test Price & Details at Chughtai Lab

Serum Anti-HIV – 1 & 2 at Chughtai Lab

The Serum Anti-HIV – 1 & 2 test is a highly sophisticated, blood-based diagnostic assay designed to detect antibodies directed against the Human Immunodeficiency Virus (HIV) types 1 and 2. HIV-1 is the most common type found globally, responsible for the vast majority of infections worldwide, while HIV-2 is less common, less pathogenic, and primarily localized to West Africa, though cases have been documented globally due to international travel and migration. This screening test is of paramount clinical importance, serving as the primary tool for identifying individuals exposed to the virus, facilitating early medical intervention, and preventing onward transmission. Chughtai Lab, a premier diagnostic network in Pakistan, utilizes advanced automated chemiluminescent microparticle immunoassay (CMIA) or enzyme-linked immunosorbent assay (ELISA) technologies to perform this test, ensuring the highest standards of sensitivity and specificity.

When a person is exposed to HIV, their immune system responds by producing specific proteins called antibodies. These antibodies target structural proteins of the virus, such as gp120 and gp41 for HIV-1, and gp36 and gp140 for HIV-2. The Serum Anti-HIV – 1 & 2 test detects these circulating antibodies in the blood serum. Because the test relies on the host's immune response, it is subject to a "window period"—the time between initial viral exposure and the production of detectable antibody levels, which typically ranges from 3 to 12 weeks. Understanding this window period is critical for accurate clinical interpretation. Early detection of HIV through this assay allows patients to access Antiretroviral Therapy (ART) promptly, which dramatically reduces viral replication, preserves immune function (specifically CD4+ T-lymphocyte counts), and transforms HIV from a once-fatal condition into a manageable chronic illness.

Clinical Procedure: What to Expect

Patient Preparation

• No Fasting Required: Patients do not need to fast before undergoing a Serum Anti-HIV – 1 & 2 test. Dietary intake does not interfere with antibody detection.
• Medication Disclosure: It is essential to inform the healthcare provider of all current medications, especially immunosuppressive therapies, pre-exposure prophylaxis (PrEP), or post-exposure prophylaxis (PEP), as these can influence the clinical context of the test.
• Hydration: Drinking adequate amounts of water prior to the blood draw is recommended to ensure veins are well-hydrated and easily accessible.
• Identification and Consent: Due to the sensitive nature of HIV testing, patients may be asked to present a valid government-issued identification card and sign an informed consent form prior to sample collection.
• Pre-Test Counseling: Chughtai Lab encourages patients to undergo brief pre-test counseling to understand the implications of both reactive and non-reactive results.

During the Procedure

The collection of a blood sample for the Serum Anti-HIV – 1 & 2 test is a standard venipuncture procedure performed by a trained phlebotomist at Chughtai Lab. The patient is comfortably seated, and the phlebotomist identifies a suitable vein, typically in the antecubital fossa (the inner bend of the elbow). The skin over the selected vein is thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) to prevent contamination. A sterile tourniquet is applied above the site to increase venous pressure, making the vein more prominent. Using a sterile, single-use needle, the phlebotomist punctures the vein and collects the blood sample into a gold-top serum separator tube (SST) or a red-top clot activator tube. Once the collection is complete, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton swab to minimize bruising. A small adhesive bandage is then applied. The entire process takes less than five minutes and involves only a mild, brief pinching sensation. The collected sample is labeled with unique barcoded patient identifiers to maintain absolute traceability and confidentiality throughout the laboratory workflow.

When is a Serum Anti-HIV – 1 & 2 Performed?

Screening for High-Risk Exposure

Physicians routinely request the Serum Anti-HIV – 1 & 2 test for individuals who have experienced potential exposure to the virus. This includes individuals who have engaged in unprotected sexual intercourse with multiple partners, individuals with a history of sexually transmitted infections (STIs), or those who have shared needles or other drug injection equipment. Additionally, healthcare workers who experience accidental occupational exposure, such as needlestick injuries, require immediate baseline testing followed by sequential monitoring to rule out transmission.

Evaluation of Clinical Symptoms

The test is clinically indicated when a patient presents with symptoms suggestive of acute retroviral syndrome or progressive immunodeficiency. During the early stages of HIV infection, patients may experience flu-like symptoms, including persistent fever, generalized lymphadenopathy (swollen lymph nodes), sore throat, maculopapular rash, myalgia, and severe fatigue. In advanced stages, symptoms such as unexplained weight loss, chronic diarrhea, recurrent oral thrush, or atypical opportunistic infections prompt immediate diagnostic evaluation via this antibody assay.

Routine Prenatal and Antenatal Screening

Obstetricians universally recommend HIV screening for all pregnant women during early prenatal care. Identifying HIV-positive status in pregnant individuals is critical because timely medical intervention, including the administration of antiretroviral drugs, planned cesarean delivery (if viral load is high), and avoiding breastfeeding, can reduce the risk of mother-to-child transmission from approximately 25-45% to less than 1%. Repeating the test in the third trimester may be indicated for those at high risk of acquiring the infection during pregnancy.

Pre-Employment and Visa Medical Requirements

Many international regulatory bodies, embassies, and employers require mandatory HIV screening as part of visa processing, residency applications, or pre-employment medical clearances. This is particularly common for individuals traveling to or working in countries with strict public health regulations. Chughtai Lab provides certified, official reports that satisfy these administrative and regulatory requirements, ensuring that the testing process is conducted with the utmost professionalism and accuracy.

Monitoring Post-Exposure Prophylaxis (PEP) Efficacy

For individuals who have initiated Post-Exposure Prophylaxis (PEP) following a high-risk sexual or occupational exposure, sequential Serum Anti-HIV – 1 & 2 testing is vital. PEP must be started within 72 hours of exposure and continued for 28 days. Antibody testing is performed at baseline (to confirm the patient was HIV-negative at the time of exposure), and then repeated at 4 to 6 weeks and 3 months post-exposure to confirm that seroconversion has not occurred and that the prophylactic regimen was successful.

What Does a Serum Anti-HIV – 1 & 2 Detect?

• Presence of HIV-1 Antibodies: Detects specific immunoglobulins (IgG and IgM) generated by the host immune system against HIV-1 viral proteins.
• Presence of HIV-2 Antibodies: Identifies antibodies targeted against HIV-2 specific envelope glycoproteins, indicating infection with this distinct viral type.
• Non-Reactive Status: Indicates that no detectable antibodies to HIV-1 or HIV-2 were found in the patient's serum at the time of testing.
• Reactive Status: Indicates the presumptive presence of antibodies to HIV-1, HIV-2, or both, requiring immediate confirmatory testing.
• Early-Stage Seroconversion: Detects the initial rise of antibodies following the window period in newly infected individuals.
• Chronic HIV-1 Infection: Identifies long-term, established HIV-1 infection in asymptomatic or symptomatic individuals.
• Chronic HIV-2 Infection: Confirms the presence of established HIV-2 infection, which features a slower clinical progression than HIV-1.
• Co-infection Status: In rare clinical scenarios, the test can detect dual reactivity to both HIV-1 and HIV-2 antigens.
• Window Period Limitations: Highlights potential false-negative scenarios where a patient is infected but has not yet developed detectable antibody levels.
• False-Positive Reactivity: Detects cross-reactive antibodies that may occur due to autoimmune diseases, recent vaccinations, or underlying hepatic disorders.
• Indeterminate Results: Identifies cases where the antibody reaction is weak or atypical, necessitating further molecular or Western Blot testing.
• Maternal Antibody Transfer: Detects maternal HIV antibodies in infants born to HIV-positive mothers (which can persist for up to 18 months, requiring PCR testing for definitive infant diagnosis).
• Baseline Immunological Status: Establishes baseline antibody negativity before a patient initiates Pre-Exposure Prophylaxis (PrEP).
• Post-Exposure Baseline Status: Confirms negative status at the time of an accidental exposure incident.
• Screening Clearance for Donors: Evaluates the safety of blood, organ, or tissue donations to prevent transfusion- or transplant-transmitted infections.
• Etiology of Opportunistic Infections: Helps identify HIV-induced immunodeficiency as the root cause of atypical infections like Pneumocystis pneumonia.
• Etiology of Persistent Lymphadenopathy: Assists in diagnosing the cause of unexplained, long-standing swelling of multiple lymph nodes.
• Etiology of Pyrexia of Unknown Origin (PUO): Investigates prolonged, unexplained fevers that may be linked to acute or chronic HIV infection.
• Etiology of Unexplained Cytopenias: Helps evaluate patients presenting with unexplained anemia, leukopenia, or thrombocytopenia associated with HIV.
• Etiology of Atypical Malignancies: Investigates potential HIV infection in patients presenting with Kaposi's sarcoma or primary central nervous system lymphoma.
• Differentiation of Viral Types: Aids in distinguishing between HIV-1 and HIV-2, which is critical because certain antiretroviral drugs are ineffective against HIV-2.
• Post-PEP Serostatus: Confirms the maintenance of a non-reactive status after completing a full course of post-exposure prophylaxis.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, the processing of the Serum Anti-HIV – 1 & 2 test is handled with extreme care, speed, and confidentiality. Utilizing fully automated, high-throughput diagnostic platforms, Chughtai Lab typically delivers test results within 12 to 24 hours of sample collection. Patients are notified via SMS as soon as their reports are finalized. To ensure maximum privacy, reports can be accessed securely online through the official Chughtai Lab website portal or the Chughtai Lab mobile application. Physical reports can also be collected from any of the numerous Chughtai Lab collection centers across Pakistan. Chughtai Lab maintains strict data protection protocols, ensuring that sensitive diagnostic information is only disclosed to the patient or their authorized healthcare provider.

Serum Anti-HIV – 1 & 2 Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HIV-1 Antibodies	Non-Reactive (Negative)	Reactive (Presumptive Positive)
HIV-2 Antibodies	Non-Reactive (Negative)	Reactive (Presumptive Positive)
Overall Screening Interpretation	No antibodies detected; no evidence of HIV infection (subject to window period)	Antibodies detected; presumptive evidence of HIV-1 or HIV-2 infection
Confirmatory Testing (if reactive)	Not applicable (not required for non-reactive screens)	Required (e.g., HIV-1/2 differentiation assay, Western Blot, or HIV RNA PCR)
Window Period Consideration	No exposure within the last 3 months	Recent high-risk exposure within 3-12 weeks (potential false-negative)
Sample Integrity / Hemolysis	Clear, non-hemolyzed serum sample	Hemolyzed, lipemic, or icteric sample (may require recollect)
Clinical Correlation Requirement	Consistent with low-risk history and absence of symptoms	Requires immediate clinical evaluation, history review, and specialist referral

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Serum Anti-HIV – 1 & 2?

• Strict Confidentiality: Chughtai Lab enforces rigorous privacy protocols to ensure your sensitive test results remain completely confidential.
• Advanced Automation: The laboratory utilizes state-of-the-art, fully automated immunoassay analyzers that deliver highly precise and reproducible results.
• ISO 15189 Certification: Chughtai Lab operates under international quality management standards, ensuring world-class diagnostic accuracy.
• Convenient Online Access: Patients can view, download, and share their reports securely via the Chughtai Lab website or mobile app.
• Nationwide Network: With hundreds of collection centers across Pakistan, accessing professional diagnostic services is convenient and accessible.
• Home Sample Collection: Highly trained, professional phlebotomists are available to collect your blood sample in the comfort and privacy of your home.
• Expert Pathologists: All diagnostic procedures and complex cases are overseen by highly qualified, experienced consultant pathologists.
• Comprehensive Support: Chughtai Lab offers dedicated customer service to assist patients with booking, report retrieval, and general inquiries.